


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-9.31%
-2.44%
+0.52%
+6.62%
JNJ
Johnson & Johnson
$219.35
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Investors confidence is positive
JNJ Price Performance
$205.78 (+6.59%)
$190.3 (+15.27%)
$175.45 (+25.02%)
$153.51 (+42.89%)
JNJ overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
JNJ Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
NBTX
21.19
+5.63%
BLTE
161.28
+1.31%
ANNX
6.99
+1.90%
SNDX
20.78
+1.24%
REGN
754.69
+0.72%
What is JNJ current stock price?
What are JNJ stock strengths?
What is JNJ Risk Level?
What is JNJ market cap and volume?
What is JNJ current Stock IQ?
Should I buy JNJ stock right now?
Is JNJ a Strong Buy right now?
What does a 'Strong Buy' rating mean for JNJ?
What does a 'Strong Sell' rating mean for JNJ?
What factors influence JNJ's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-9.31%
-2.44%
+0.52%
+6.62%
JNJ
Johnson & Johnson
Current Price
$219.35
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Investors confidence is positive
Linked to JNJ
NBTX
21.19
+5.63%
BLTE
161.28
+1.31%
ANNX
6.99
+1.90%
SNDX
20.78
+1.24%
REGN
754.69
+0.72%

JNJ Price Performance
$205.78 (+6.59%)
$190.3 (+15.27%)
$175.45 (+25.02%)
$153.51 (+42.89%)
JNJ Analysts Opinion
JNJ Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
JNJ Analysts opinion is negative and has getting worse from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
JNJ has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
Dec 17, 2025
Price Target Raised
Neutral
BofA
Dec 12, 2025
Reiterate
Outperform
RBC
Dec 12, 2025
Reiterate
Buy
Citigroup
Dec 11, 2025
Reiterate
Buy
Guggenheim
Dec 05, 2025
Reiterate
Buy
Guggenheim
JNJ Stock IQ
JNJ Latest Analysis
Noteworthy ETF Outflows: IWB JNJ MA ABBV. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $244.5 million dollar outflow -- thats a 0.5% decrease week over week
Today
Jim Cramer on Johnson & Johnson: One of the Best Pharmas There Is.
Today
Is This Dividend King Stock a Buy After a Major Development?. Key PointsJohnson & Johnson signed a deal to avoid tariffs.
Today
Plaintiffs Evidence Will Be Heard in Cases Alleging J&Js Talc Products Caused Womens Ovarian Cancer Announced Levin Papantonio Attorney Chris Tisi. PENSACOLA Fla. Jan. 21 2026 (GLOBE NEWSWIRE) -- A United States District Court Special Master in the talc multidistrict litigation (MDL) against Johnson &. Johnson (J&.J) entered an Opinion reaffirming that plaintiffs may present expert testimony supporting general causation to the jury. Specifically Special Master Hon. L. Wolfson former Chief
Today
This 2.4%-Yielding Dividend King Remains As Healthy As Ever. Key PointsJohnson & Johnson has increased its dividend each year for over half a century.
Today
MDAI: In the Blocks Ready to Go upon Mid-Year Authorization. By It has now been approximately seven months since Spectral AI Inc. (NASDAQ:MDAI) announced its De Novo marketing application to the FDA for the DeepView device. Based on historical review times and no mention of unexpected delays we anticipate that an authorization by the FDA for the DeepView device could come mid-year. We had a chance to catch up with management which remains focused on commercialization preparation activities and i
Wed Jan 21, 2026
Nasdaq Edges Lower. Johnson & Johnson Earnings Top Estimates. United States stocks traded mixed midway through trading with the Nasdaq Composite moving lower on Wednesday.The Dow traded up 0.30% to 48632.75 while the NASDAQ fell 0.06% to 22940.77. The S&.P 500 also rose gaining 0.16% to 6807.83.Energy shares gained by 2% on Wednesday.In trading on Wednesday consumer staples stocks dipped by 0.5%.) on Wednesday reported better-than-expected fourth-quarter earnings.The company posted adjusted e
Wed Jan 21, 2026
Johnson & Johnson outlines double-digit growth ambition by end of decade as 2026 sales set to surpass $100B.
Wed Jan 21, 2026
Dow Movers: JNJ TRV. In early trading on Wednesday shares of Travelers Companies topped the list of the days best performing Dow Jones Industrial Average components trading up 2.1%. Year to date Travelers Companies has lost about 5.1% of its value.And the worst performing Dow component thus f
Wed Jan 21, 2026
J&J Stock Down Despite Q4 Earnings Beat Oncology Drugs Drive Sales. JNJ beat Q4 earnings and sales estimates as strong oncology drug growth led by Darzalex offset biosimilar pressure on Stelara.
Wed Jan 21, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.